HER2 splice variants and their relevance in breast cancer

Marianna Sasso, Francesca Bianchi, Valentina Ciravolo, Elda Tagliabue, Manuela Campiglio

Research output: Contribution to journalArticle

Abstract

The HER2 gene amplification occurs in 20-30% of breast cancer and is correlated with a poorer prognosis compared to HER2-negative disease due to increased proliferation and metastatic potential. Two major types of receptor inhibitors have been developed for therapy and one for each categories is currently used in clinic: i) the humanized monoclonal antibody trastuzumab, directed against the HER2 extracellular domain; and ii) the EGFR/HER2 dual tyrosine kinase inhibitor lapatinib. However, patients may develop resistance to drugs and show disease progression. Several mechanism of resistance have been explored and are still under investigation. Here, we focus our attention on the role played by the alternative splicing forms of HER2 in mediating HER2 oncogenic activity and in conditioning the response to HER2 therapies. Three HER2 splice variants have been described so far; the p100 and the herstatin give raise to two secreted proteins of 100 kd and 68 kd, respectively, that act as cell growth inhibitors. The third splice form of HER2 gene is the Δ16HER2, encoding for a receptor lacking exon16, whose absence determines constitutive active dimers with transforming activity in vitro and in vivo. The Δ16HER2 binds to trastuzumab to a less extend, due to conformational changes of the extracellular domain and its levels are supposed to increase proportionally to the increasing of the HER2 wild-type copy numbers in human primary breast cancers. Finally, HER2 carboxy-terminal fragments (CTFs), generated by alternative initiation of translation, were observed in breast cancer patients. In particular, 611-CTF, activating multiple signaling pathways since it is expressed as a constitutively active homodimer, was suggested to be a potent oncogene capable of promoting mammary tumour progression and metastasis. Despite the evidences of a potential role of the naturally occurring inhibitors p100 and herstatin on the wild-type HER2 and its signaling pathway, to date they do not seem to have a possible clinical development. To date the most promising forms currently under investigation that could have a key role in determining the increased HER2-positive tumours aggressiveness and toward the development of bio-drugs are the HER2Δ16 and the CTFs.

Original languageEnglish
Pages (from-to)52-59
Number of pages8
JournalJournal of Nucleic Acids Investigation
Volume2
Issue number1
DOIs
Publication statusPublished - 2011

Fingerprint

Tumors
Breast Neoplasms
erbB-2 Genes
Antibodies, Monoclonal, Humanized
Growth Inhibitors
Alternative Splicing
Pharmaceutical Preparations
Dimers
Protein-Tyrosine Kinases
Genes
Gene Amplification
Oncogenes
Drug Resistance
Disease Progression
Proteins
Neoplasm Metastasis
herstatin
Trastuzumab
Therapeutics
Neoplasms

Keywords

  • Breast cancer
  • ECD
  • HER2
  • HER2delta16
  • Herstatin

ASJC Scopus subject areas

  • Biochemistry

Cite this

HER2 splice variants and their relevance in breast cancer. / Sasso, Marianna; Bianchi, Francesca; Ciravolo, Valentina; Tagliabue, Elda; Campiglio, Manuela.

In: Journal of Nucleic Acids Investigation, Vol. 2, No. 1, 2011, p. 52-59.

Research output: Contribution to journalArticle

Sasso, Marianna ; Bianchi, Francesca ; Ciravolo, Valentina ; Tagliabue, Elda ; Campiglio, Manuela. / HER2 splice variants and their relevance in breast cancer. In: Journal of Nucleic Acids Investigation. 2011 ; Vol. 2, No. 1. pp. 52-59.
@article{6cb1c4b86071419a84a181c8ec6184ab,
title = "HER2 splice variants and their relevance in breast cancer",
abstract = "The HER2 gene amplification occurs in 20-30{\%} of breast cancer and is correlated with a poorer prognosis compared to HER2-negative disease due to increased proliferation and metastatic potential. Two major types of receptor inhibitors have been developed for therapy and one for each categories is currently used in clinic: i) the humanized monoclonal antibody trastuzumab, directed against the HER2 extracellular domain; and ii) the EGFR/HER2 dual tyrosine kinase inhibitor lapatinib. However, patients may develop resistance to drugs and show disease progression. Several mechanism of resistance have been explored and are still under investigation. Here, we focus our attention on the role played by the alternative splicing forms of HER2 in mediating HER2 oncogenic activity and in conditioning the response to HER2 therapies. Three HER2 splice variants have been described so far; the p100 and the herstatin give raise to two secreted proteins of 100 kd and 68 kd, respectively, that act as cell growth inhibitors. The third splice form of HER2 gene is the Δ16HER2, encoding for a receptor lacking exon16, whose absence determines constitutive active dimers with transforming activity in vitro and in vivo. The Δ16HER2 binds to trastuzumab to a less extend, due to conformational changes of the extracellular domain and its levels are supposed to increase proportionally to the increasing of the HER2 wild-type copy numbers in human primary breast cancers. Finally, HER2 carboxy-terminal fragments (CTFs), generated by alternative initiation of translation, were observed in breast cancer patients. In particular, 611-CTF, activating multiple signaling pathways since it is expressed as a constitutively active homodimer, was suggested to be a potent oncogene capable of promoting mammary tumour progression and metastasis. Despite the evidences of a potential role of the naturally occurring inhibitors p100 and herstatin on the wild-type HER2 and its signaling pathway, to date they do not seem to have a possible clinical development. To date the most promising forms currently under investigation that could have a key role in determining the increased HER2-positive tumours aggressiveness and toward the development of bio-drugs are the HER2Δ16 and the CTFs.",
keywords = "Breast cancer, ECD, HER2, HER2delta16, Herstatin",
author = "Marianna Sasso and Francesca Bianchi and Valentina Ciravolo and Elda Tagliabue and Manuela Campiglio",
year = "2011",
doi = "10.4081/jnai.2011.e8",
language = "English",
volume = "2",
pages = "52--59",
journal = "Journal of Nucleic Acids Investigation",
issn = "2036-7996",
publisher = "PagePress",
number = "1",

}

TY - JOUR

T1 - HER2 splice variants and their relevance in breast cancer

AU - Sasso, Marianna

AU - Bianchi, Francesca

AU - Ciravolo, Valentina

AU - Tagliabue, Elda

AU - Campiglio, Manuela

PY - 2011

Y1 - 2011

N2 - The HER2 gene amplification occurs in 20-30% of breast cancer and is correlated with a poorer prognosis compared to HER2-negative disease due to increased proliferation and metastatic potential. Two major types of receptor inhibitors have been developed for therapy and one for each categories is currently used in clinic: i) the humanized monoclonal antibody trastuzumab, directed against the HER2 extracellular domain; and ii) the EGFR/HER2 dual tyrosine kinase inhibitor lapatinib. However, patients may develop resistance to drugs and show disease progression. Several mechanism of resistance have been explored and are still under investigation. Here, we focus our attention on the role played by the alternative splicing forms of HER2 in mediating HER2 oncogenic activity and in conditioning the response to HER2 therapies. Three HER2 splice variants have been described so far; the p100 and the herstatin give raise to two secreted proteins of 100 kd and 68 kd, respectively, that act as cell growth inhibitors. The third splice form of HER2 gene is the Δ16HER2, encoding for a receptor lacking exon16, whose absence determines constitutive active dimers with transforming activity in vitro and in vivo. The Δ16HER2 binds to trastuzumab to a less extend, due to conformational changes of the extracellular domain and its levels are supposed to increase proportionally to the increasing of the HER2 wild-type copy numbers in human primary breast cancers. Finally, HER2 carboxy-terminal fragments (CTFs), generated by alternative initiation of translation, were observed in breast cancer patients. In particular, 611-CTF, activating multiple signaling pathways since it is expressed as a constitutively active homodimer, was suggested to be a potent oncogene capable of promoting mammary tumour progression and metastasis. Despite the evidences of a potential role of the naturally occurring inhibitors p100 and herstatin on the wild-type HER2 and its signaling pathway, to date they do not seem to have a possible clinical development. To date the most promising forms currently under investigation that could have a key role in determining the increased HER2-positive tumours aggressiveness and toward the development of bio-drugs are the HER2Δ16 and the CTFs.

AB - The HER2 gene amplification occurs in 20-30% of breast cancer and is correlated with a poorer prognosis compared to HER2-negative disease due to increased proliferation and metastatic potential. Two major types of receptor inhibitors have been developed for therapy and one for each categories is currently used in clinic: i) the humanized monoclonal antibody trastuzumab, directed against the HER2 extracellular domain; and ii) the EGFR/HER2 dual tyrosine kinase inhibitor lapatinib. However, patients may develop resistance to drugs and show disease progression. Several mechanism of resistance have been explored and are still under investigation. Here, we focus our attention on the role played by the alternative splicing forms of HER2 in mediating HER2 oncogenic activity and in conditioning the response to HER2 therapies. Three HER2 splice variants have been described so far; the p100 and the herstatin give raise to two secreted proteins of 100 kd and 68 kd, respectively, that act as cell growth inhibitors. The third splice form of HER2 gene is the Δ16HER2, encoding for a receptor lacking exon16, whose absence determines constitutive active dimers with transforming activity in vitro and in vivo. The Δ16HER2 binds to trastuzumab to a less extend, due to conformational changes of the extracellular domain and its levels are supposed to increase proportionally to the increasing of the HER2 wild-type copy numbers in human primary breast cancers. Finally, HER2 carboxy-terminal fragments (CTFs), generated by alternative initiation of translation, were observed in breast cancer patients. In particular, 611-CTF, activating multiple signaling pathways since it is expressed as a constitutively active homodimer, was suggested to be a potent oncogene capable of promoting mammary tumour progression and metastasis. Despite the evidences of a potential role of the naturally occurring inhibitors p100 and herstatin on the wild-type HER2 and its signaling pathway, to date they do not seem to have a possible clinical development. To date the most promising forms currently under investigation that could have a key role in determining the increased HER2-positive tumours aggressiveness and toward the development of bio-drugs are the HER2Δ16 and the CTFs.

KW - Breast cancer

KW - ECD

KW - HER2

KW - HER2delta16

KW - Herstatin

UR - http://www.scopus.com/inward/record.url?scp=80052220164&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=80052220164&partnerID=8YFLogxK

U2 - 10.4081/jnai.2011.e8

DO - 10.4081/jnai.2011.e8

M3 - Article

AN - SCOPUS:80052220164

VL - 2

SP - 52

EP - 59

JO - Journal of Nucleic Acids Investigation

JF - Journal of Nucleic Acids Investigation

SN - 2036-7996

IS - 1

ER -